Medicare Enrolled
Dr. Nanda Biswas, M.D.
Hematology & Oncology · Victorville, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Biswas from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Biswas?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Biswas
Dr. Nanda Biswas is a hematology & oncology specialist in Victorville, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Biswas performed 6,664 Medicare services across 988 unique beneficiaries.
Between the years covered by Open Payments, Dr. Biswas received a total of $26,439 from 79 pharmaceutical and/or device companies across 1233 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Biswas is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 31% volume in CA
$26,439 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,664
Medicare services
Top 31% in CA for hematology & oncology
988
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~351 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, heparin sodium, (heparin lock flush), per 10 units | 3,302 | $0 | $5 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,100 | $66 | $95 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
660 | $0 | $10 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
348 | $0 | $93 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
275 | $99 | $150 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
264 | $55 | $125 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
234 | $108 | $200 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
95 | $111 | $275 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
82 | $54 | $225 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
82 | $25 | $125 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
63 | $13 | $100 |
| EKG interpretation and report A standard electrocardiogram test that records the heart's electrical activity using at least 12 leads. The service includes a professional interpretation of the results and a written report. |
58 | $7 | $20 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
56 | $128 | $250 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
23 | $126 | $175 |
| Bone marrow aspiration A procedure to remove a small sample of liquid bone marrow for diagnostic testing. |
11 | $67 | $334 |
| Biopsy of bone marrow | 11 | $139 | $375 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.1% high complexity
60.6% medium
30.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$26,439
Total received (2018-2024)
Avg $3,777/year across 7 years
Top 17% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
79
Companies
1,233
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,197 (84.0%)
Other
Charitable contributions, space rental, and other categories
$3,643 (13.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$600 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,846
2023
$4,859
2022
$4,405
2021
$4,728
2020
$2,918
2019
$1,805
2018
$2,879
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,396
AstraZeneca Pharmaceuticals LP
$599
Janssen Biotech, Inc.
$375
E.R. Squibb & Sons, L.L.C.
$234
ABBVIE INC.
$231
BeiGene USA, Inc.
$222
Astellas Pharma US Inc
$206
Ipsen Biopharmaceuticals, Inc
$181
SOBI, INC
$159
PFIZER INC.
$121
Gilead Sciences, Inc.
$89
Bayer Healthcare Pharmaceuticals Inc.
$75
Karyopharm Therapeutics Inc.
$73
PUMA BIOTECHNOLOGY, INC.
$70
Merck Sharp & Dohme LLC
$69
Lilly USA, LLC
$66
Amgen Inc.
$63
GlaxoSmithKline, LLC.
$62
Incyte Corporation
$51
Genentech USA, Inc.
$48
ARRAY BIOPHARMA INC
$48
Alexion Pharmaceuticals, Inc.
$46
Regeneron Healthcare Solutions, Inc.
$44
GENZYME CORPORATION
$42
Telix Pharmaceuticals
$38
PharmaEssentia USA Corporation
$31
Novo Nordisk Inc
$30
Celgene Corporation
$30
Rigel Pharmaceuticals, Inc.
$29
EMD Serono, Inc.
$29
Alnylam Pharmaceuticals Inc.
$29
SpringWorks Therapeutics, Inc.
$23
Sumitomo Pharma America, Inc.
$20
RedHill Biopharma Inc.
$19
Top 3 companies account for 48.9% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$4,233
E.R. Squibb & Sons, L.L.C.
$2,066
AstraZeneca Pharmaceuticals LP
$1,806
PFIZER INC.
$1,590
Janssen Biotech, Inc.
$1,565
Astellas Pharma US Inc
$1,103
Incyte Corporation
$779
Lilly USA, LLC
$728
Regeneron Healthcare Solutions, Inc.
$601
Celgene Corporation
$558
GlaxoSmithKline, LLC.
$516
Bayer HealthCare Pharmaceuticals Inc.
$510
Novo Nordisk Inc
$482
BeiGene USA, Inc.
$454
Zimmer Biomet Holdings, Inc.
$434
Rigel Pharmaceuticals, Inc.
$426
SANOFI-AVENTIS U.S. LLC
$419
Alexion Pharmaceuticals, Inc.
$409
Merck Sharp & Dohme Corporation
$399
Bayer Healthcare Pharmaceuticals Inc.
$396
Takeda Pharmaceuticals U.S.A., Inc.
$379
Puma Biotechnology, Inc.
$370
Genentech USA, Inc.
$329
Pharmacyclics LLC, An AbbVie Company
$314
Amgen Inc.
$306
Merck Sharp & Dohme LLC
$305
Boehringer Ingelheim Pharmaceuticals, Inc.
$263
Seagen Inc.
$257
NOVARTIS PHARMACEUTICALS CORPORATION
$250
ABBVIE INC.
$231
Janssen Pharmaceuticals, Inc
$230
GENZYME CORPORATION
$208
Gilead Sciences, Inc.
$207
EMD Serono, Inc.
$207
Sumitomo Pharma America, Inc.
$203
PUMA BIOTECHNOLOGY, INC.
$190
Medicure Pharma Inc.
$187
Pharmacyclics LLC, an AbbVie Company
$183
Ipsen Biopharmaceuticals, Inc
$181
SOBI, INC
$174
Karyopharm Therapeutics Inc.
$173
Myovant Sciences Inc.
$131
Alnylam Pharmaceuticals Inc.
$117
SUN PHARMACEUTICAL INDUSTRIES INC.
$109
TESARO, Inc.
$103
Dova Pharmaceuticals
$93
Sobi, Inc
$91
Octapharma USA, Inc.
$84
AVEO Pharmaceuticals, Inc.
$77
Teva Pharmaceuticals USA, Inc.
$69
Daiichi Sankyo Inc.
$68
ARRAY BIOPHARMA INC
$67
TOLMAR Pharmaceuticals, Inc.
$58
AbbVie Inc.
$54
AbbVie, Inc.
$53
Blue Earth Diagnostics Limited
$53
Kite Pharma, Inc.
$49
Clovis Oncology, Inc.
$48
Telix Pharmaceuticals
$38
Dendreon Pharmaceuticals LLC
$37
EISAI INC.
$36
PharmaEssentia USA Corporation
$31
Coherus Biosciences Inc.
$30
Emmaus Medical, Inc.
$27
Xeris Pharmaceuticals, Inc.
$24
Eisai Inc.
$23
Sun Pharmaceutical Industries Inc.
$23
SpringWorks Therapeutics, Inc.
$23
Horizon Therapeutics plc
$23
ADC Therapeutics America, Inc.
$22
Seattle Genetics, Inc.
$21
RedHill Biopharma Inc.
$19
Epizyme, Inc.,
$19
Aurobindo Pharma USA, Inc.
$18
ImmunoGen, Inc.
$18
Taiho Oncology, Inc.
$17
Foundation Medicine, Inc.
$17
Mirati Therapeutics, Inc.
$16
Pharming Healthcare, Inc.
$15
Top 3 companies account for 30.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AIRSUPRA · AUGTYRO · Alecensa · Axumin · BAVENCIO · BELSOMRA · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BREZTRI · BRUKINSA · BYDUREON · Bavencio · Blincyto · CALQUENCE · CHANTIX · COLOGUARD · CYRAMZA · DARZALEX · DOPTELET · DRIZALMA SPRINKLE · Dayvigo · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENTRESTO · EPKINLY · ERLEADA · Elahere · Endari · Enhertu · Erleada · FARXIGA · FOTIVDA · FOUNDATIONONE · Fabhalta · Folotyn · GILOTRIF · GIVLAARI · GVOKE HYPOPEN · HMG-CoA reductase inhibitor. · Herceptin · IBRANCE · ICLUSIG · ILLUCCIX · IMBRUVICA · IMFINZI · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JANUVIA · JARDIANCE · JEVTANA · KAPSPARGO · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kadcyla · Kerendia · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MOUNJARO · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nexavar · Novoeight · Nplate · Nubeqa · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · OXLUMO · Onivyde · Otezla · Ozempic · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Perjeta · Phesgo · Pomalyst · REBLOZYL · RUCONEST · RYBELSUS · RYBREVANT · Revlimid · Rezlidhia · Rib Fix Blu · Rubraca · Rybelsus · SARCLISA · SCEMBLIX · SOLIQUA · SOLIQUA 100/33 · SOLIRIS · STIOLTO RESPIMAT · SUTENT · SYMBICORT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TMS · TOUJEO · TRELEGY ELLIPTA · TRULICITY · Talicia · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Venclexta · Victoza · Vyloy · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xospata · Xtandi · YONSA · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
6
Per 100K population
0.3
County median income
$82,184
Nearest hospital
VICTOR VALLEY GLOBAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Biswas is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 17% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Biswas experienced with injection, heparin sodium, (heparin lock flush), per 10 units?
Based on Medicare claims data, Dr. Biswas performed 3,302 injection, heparin sodium, (heparin lock flush), per 10 units services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Biswas receive payments from pharmaceutical companies?
Yes. Dr. Biswas received a total of $26,439 from 79 companies across 1,233 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Biswas's costs compare to other hematology & oncology specialists in Victorville?
Dr. Biswas's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Biswas) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Victorville
Browse hematology & oncology specialists in Victorville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology